Author:
Toshida Katsuya,Itoh Shinji,Toshima Takeo,Yoshiya Shohei,Bekki Yuki,Izumi Takuma,Iseda Norifumi,Nakayama Yuki,Ishikawa Takuma,Yoshizumi Tomoharu
Funder
Research Grant from the Princess Takamatsu Cancer Research Fund
Kobayashi Foundation for Cancer Research
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14.
2. Vogel A, Saborowski A. Medical therapy of HCC. J Hepatol. 2022;76(1):208–10.
3. Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3(4):386–401.
4. Itoh S, Yoshizumi T, Yugawa K, Imai D, Yoshiya S, Takeishi K, et al. Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation. Hepatology. 2020;72(6):1987–99.
5. Itoh S, Yugawa K, Shimokawa M, Yoshiya S, Mano Y, Takeishi K, et al. Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection. BJS Open. 2019;3(4):500–8.